Latest news
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade) - Seeking AlphaSeeking Alpha · Mon, 10 Aug 2026 13:16:20 GMTCan Gilead Sciences (NASDAQ:GILD) Turn Research Into Growth? - Kalkine MediaKalkine Media · Fri, 07 Aug 2026 16:16:00 GMTGilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained - TipRanksTipRanks · Wed, 05 Aug 2026 19:50:05 GMTGILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure - StockStoryStockStory · Wed, 05 Aug 2026 16:57:13 GMTGilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability - Fierce PharmaFierce Pharma · Wed, 05 Aug 2026 14:44:51 GMTShionogi (TSE:4507) Stock Dips Despite Strong Margins And Product Momentum - simplywall.stsimplywall.st · Tue, 04 Aug 2026 16:58:41 GMT